Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
about
Recognition of nucleic acid junctions using triptycene-based molecules.Toward the design of a catalytic metallodrug: selective cleavage of G-quadruplex telomeric DNA by an anticancer copper-acridine-ATCUN complexMechanistic Studies of the Anticancer Activity of An Octahedral Hexanuclear Pt(II) Cage.Comparison of the π-stacking properties of purine versus pyrimidine residues. Some generalizations regarding selectivity.Biologically active [Pd2L4](4+) quadruply-stranded helicates: stability and cytotoxicity.Luminescent cyclometalated platinum(II) complex forms emissive intercalating adducts with double-stranded DNA and RNA: differential emissions and anticancer activities.Iron(II) supramolecular helicates interfere with the HIV-1 Tat-TAR RNA interaction critical for viral replication.Oxidatively Locked [Co₂L₃]6+ Cylinders Derived from Bis(bidentate) 2-Pyridyl-1,2,3-triazole "Click" Ligands: Synthesis, Stability, and Antimicrobial Studies.Catalytic Metallodrugs: Substrate-Selective Metal Catalysts as Therapeutics.TWJ-Screen: an isothermal screening assay to assess ligand/DNA junction interactions in vitro.Enantioselective targeting left-handed Z-G-quadruplex.Iron(II) supramolecular helicates condense plasmid DNA and inhibit vital DNA-related enzymatic activities.Metallo supramolecular cylinders inhibit HIV-1 TAR-TAT complex formation and viral replication in celluloCationic azacryptands as selective three-way DNA junction binding agentsPhoto-induced uncaging of a specific Re(i) organometallic complex in living cells
P2860
Q34694681-8D688FAB-3F18-4373-B6BB-D7020DD45F81Q35518250-650DCA13-3E06-448A-987C-DF579C65BFD9Q37392185-2F223598-15DF-4FD8-AEA5-6C264E451DBEQ38181953-A8953ACE-910D-4741-9F01-32D83BD7CCCAQ38872477-30406B97-218A-456C-A395-05DBACFFD7A4Q38973433-B24CDFC4-18D3-4507-9527-CD388F4A2E5BQ40655184-9C766E4E-5627-4B35-BA24-7AEA56239EF2Q46071418-18A969D4-3A6D-43F0-9754-70C8167F693BQ48157762-4609D5EE-B1F2-4E5F-99A7-2028BE22429EQ49921894-967144C7-485E-4CFC-94C6-B834D66B0265Q53401327-4A7F3EC4-BD2C-4B42-9B39-382CF1EE33D3Q53457259-8417F24D-B586-4190-BB30-9D2398839348Q58761926-68181BE7-25B8-406E-B096-7DC1B93A37A0Q59240519-5C3B9B66-D421-4E4B-A8EC-8B41A6CB12DDQ59265339-3DB8913C-8F2F-44F0-947F-F48AB23DF45C
P2860
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@ast
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@en
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@nl
type
label
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@ast
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@en
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@nl
prefLabel
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@ast
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@en
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@nl
P2093
P2860
P50
P356
P1476
Binding of a designed anti-cancer drug to the central cavity of an RNA three-way junction
@en
P2093
Michael J Hannon
Siriporn Phongtongpasuk
Susann Paulus
P2860
P304
11513-11516
P356
10.1002/ANIE.201305079
P407
P577
2013-10-25T00:00:00Z